Cargando…
Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292133/ https://www.ncbi.nlm.nih.gov/pubmed/32743408 http://dx.doi.org/10.1002/iju5.12073 |